47 Rue Adrienne Bolland
Ncardia innovative hiPSC-based products and services for drug discovery & cell therapy
Ncardia was formed in August 2017 following an acquisition by Pluriomics. Pluriomics was founded in 2011 by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.
Ncardia is a leader in contract research and contract development and manufacture of human induced pluripotent stem cell-based drug discovery and cell therapy solutions. Our capabilities include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. Ncardia is a dedicated team of iPSC experts that uses our industry knowledge and experience to develop and deliver innovative stem cell-based services to serve our customers.
The Board of Directors of Ncardia consists of:
Ncardia is a privately held Belgium-based company with subsidiaries in the Netherlands and the USA. The investor base of the company includes both public and private funds including Vesalius Biocapital, SFPI-FPIM, SambrInvest, InnovationQuarter, S.R.I.W, Sino-German beta Holding Co. Ltd and founders.
Ncardia has attracted a leadership team of international experts in the areas of commercialization, pharma services, finance, stem cell R&D and manufacturing.
The management team consists of: